Prothena Corporation plc is a late-stage clinical
         biotechnology company with a portfolio of
      novel monoclonal antibodies that may offer
   new treatments for diseases that
involve amyloid or cell adhesion.

LATEST NEWS

SPOTLIGHT

Potential Mechanism of Action (MOA) Videos:

vid_neod001
for AL Amyloidosis
vid_prx002
for Parkinson’s Disease and
Other Related Synucleinopathies
vid_prx003
for Psoriasis and Other
Inflammatory Diseases